Several recent clinical trials have demonstrated the efficacy of angiotensin AT1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEI) in primary and secondary prevention of stroke in patients with hypertension and/or high cardiovascular risk [1]–[6]. Here, ACE is linked to stroke disorder.